Specificity Study Of The Binding Of Human Prostatic Carcinoma Cell PC3M Invasive Associated Protein

Prostate cancer(PC)is one of the most common carcinomas in male Urogenital System. With the development of diagnostic techniques and the aggravation of social ageing, the incidence of prostate cancer is continuously increasing in our country. This is the third one in the carcinomas of male Urogenital System. Reports indicated that about one third prostate cancer patients had already been enduring metastasis at first diagnosis,bone metastasis is the most common condition. More than three quarters would suffer bone metastasis during the whole disease course, such as in the pelvis, spine and femur. The metastasis of PC is the predominant factor causing death. Thus, in a long future, the invasion and metastasis of tumor cells will be the key problem for human to conquer cancer.Despite the initial effectiveness of hormone therapy, many patients with metastatic disease eventually progress to an androgen-resistant state. Various new treatment modalities are currently being developed, but none has yet shown a survival benefit in patients with hormone-refractory prostate cancer. Therefore, to find a related molecule that can reverse prostate cancer metastasis is the key point on treating prostate cancer for human being in the future.Traditional directed therapy is to be regard as important and become hot point in studying increasingly, because its advantage of selectively killing cells. Monoclonal antibody is used as a vector in the traditional directed therapy. At present there are still some defects can not be overcome. We can obtain the short peptide specifically binding on human prostate cancer cell lines PC3M by subtractive screening in phage random peptide library. This study selected the peptide No.B04 which most consistent with the consensus sequence from 14-specific peptides. We detected its expression in all normal human tissues, organs and prostate hyperplasia by immunohistochemisty. These studies provide a basis for targeted drug design and bring new hope for clinical treatment of prostate cancer.The results are as follows: The specific short peptide binding with human prostatic carcinoma cell invasive associated protein have affinity with Islet cells, but have no binding with human Brain, heart, liver, kidney, larynx, trachea, lung, lymph nodes, spleen, intestine, pituitary, adrenal gland all 12 kinds of tissues and organs and have no expression in benign prostatic hyperplasia.Summary, we obtained the short peptide specifically binding on human prostate cancer cells by subtractive screening in phage random peptide library. Then we systematically identify its expression in all normal human tissues, organs and prostate hyperplasia by immunohistochemisty to define the specificity of the short peptide. This study provided evidence for the targeted drug design and laid the foundation for the development of anti-tumor drugs.